QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model
QLT0267 是一种靶向整合素连接激酶 (ILK) 的小分子抑制剂，与多西他赛联合使用可产生协同作用，从而增强细胞毒性、降低 P-AKT 水平、改变 F-肌动蛋白结构，并在原位乳腺癌模型中改善治疗效果。
期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/bcr2252
Kalra, Jessica; Warburton, Corinna; Fang, Karen; Edwards, Lincoln; Daynard, Tim; Waterhouse, Dawn; Dragowska, Wieslawa; Sutherland, Brent W; Dedhar, Shoukat; Gelmon, Karen; Bally, Marcel
肿瘤
肿瘤免疫
信号转导
ILK
乳腺癌
AKT
细胞生物学
毒理研究
